BETALIN THERAPEUTICS LTD

Their core work

Betalin Therapeutics is an Israeli biotech SME developing cell therapy solutions for diabetes treatment. Their core technology revolves around tissue-derived acellular micro-scaffolds and engineered micro-pancreas constructs designed to restore insulin production in diabetic patients. They build 3D cellular models for diabetes R&D and are advancing injectable cell therapies that aim to reduce or eliminate insulin dependence. All three of their H2020 projects focus exclusively on diabetes, progressing from feasibility (SME Phase 1) through development and clinical translation.

What they specialise in

How they've shifted over time

Betalin started in 2017 with a small feasibility study (Io-EMP, EUR 50K) exploring acellular micro-scaffold technology to reduce insulin dependence — a classic SME Phase 1 concept validation. By 2020, they secured two substantially larger projects simultaneously: one focused on 3D modeling tools for diabetes R&D (Cells in Matrix) and another on injectable micro-pancreas cell therapy (Micro Pancreas, EUR 2.45M). The trajectory shows a clear progression from early-stage feasibility toward clinical-scale therapeutic development and parallel investment in R&D infrastructure.

Betalin is scaling from proof-of-concept toward clinical-grade injectable cell therapies for diabetes, suggesting they will seek partners with GMP manufacturing, clinical trial, and regulatory expertise.

How they like to work

Betalin coordinates all three of their H2020 projects — they always lead, never participate as a partner. Their consortia are small (only 4 unique partners across 3 projects in 3 countries), indicating they prefer tight, focused teams rather than large multi-partner consortia. This is typical for a deep-tech SME protecting core IP while selectively bringing in complementary expertise.

Betalin has worked with only 4 unique partners across 3 countries, maintaining a compact and selective collaboration network. Their partnerships are likely concentrated around specific technical needs rather than broad geographic coverage.

What sets them apart

Betalin occupies a rare niche: an SME developing injectable micro-pancreas constructs as a potential cure for diabetes, not just a management tool. Their combination of 3D scaffold engineering with cell therapy positions them at the intersection of regenerative medicine and diabetes care — a space where most competitors are either large pharma or academic labs. For consortium builders, they bring deep domain focus, proven ability to win and coordinate EU funding, and a clear translational pipeline from lab to therapy.

Highlights from their portfolio

• Micro Pancreas
  Largest project (EUR 2.45M) aiming to cure diabetes through injectable micro-pancreas cell therapy — a bold therapeutic goal with significant commercial potential.
• Cells in Matrix
  Developed a 3D diabetes R&D model that could serve as a platform technology for drug testing and therapy development beyond Betalin's own pipeline.
• Io-EMP
  The SME Phase 1 seed project that validated the core micro-scaffold concept, demonstrating Betalin's progression from feasibility to full-scale development.